The autonomic nervous system (ANS) is essential for regulating involuntary physiological functions like heart rate, respiration rate, digestion rate, and blood pressure. Disturbances in ANS function can lead to a variety of clinical disorders, including autonomic neuropathy, arrhythmias, and excessive blood pressure. Recent breakthroughs in pharmacotherapy have made it possible to control these disorders more effectively. Drugs that alter the autonomic balance, particularly those that target receptors involved in sympathetic and parasympathetic pathways of signalling, have been the focus of recent developments. Alpha-agonists, muscarinic antagonists, and beta-blockers have all been used extensively to treat conditions related to the heart and breathing. To restore autonomic balance, new techniques include gene treatments and the use of selective receptor modulators. Certain beta-adrenergic receptor antagonists and new calcium channel blockers have demonstrated encouraging impacts in cardiovascular pharmacology especially when it comes to reducing heart rate variability while improving outcomes for individuals with autonomic dysfunction. Furthermore, novel medications that target the neurohormonal systems such as aldosterone antagonists and angiotensin receptor blockers are being investigated for their capability to lessen autonomic neuropathy symptoms. More focused treatments that reduce side effects and improve patient compliance are also being researched as a result of advances in our understanding of autonomic function at the molecular and cellular levels. Additionally, the precision of ANS pharmacotherapeutics is being improved through incorporating the use of personalized medicine through pharmacogenomics. To sum up, the continuous advancements in autonomic pharmacotherapy may lead to better clinical results and patient quality of life for patients with autonomic-related illnesses. The establishment of next-generation treatments will require more investigation into the molecular mechanisms behind autonomic control.
Clinical disorder, Cardiovascular pharmacology, Neurohormonal systems, Cerebral cortex
Abel, A. C. C. J. (2009). On the blood-pressure-raising constituent of the suprarenal capsule. BiblioBazaar, LLC.
Abel, J. J. (1898). Further observations on the chemical nature of the active principle of the suprarenal capsule.
Acheson, G. H., & Moe, G. K. (1946). The action of tetraethylammonium ion on the mammalian circulation. The Journal of Pharmacology and Experimental Therapeutics, 87(3), 220-236.
Ackerknecht, E. H. (1974). The history of the discovery of the vegetative (autonomic) nervous system. Medical history, 18(1), 1-8.
Adrian, E. D., Bronk, D. W., & Phillips, G. (1932). Discharges in mammalian sympathetic nerves. The Journal of physiology, 74(2), 115.
Akiyama, T., & Yamazaki, T. (2000). Adrenergic inhibition of endogenous acetylcholine release on postganglionic cardiac vagal nerve terminals. Cardiovascular research, 46(3), 531-538.
Alway, S. E., Hughson, R. L., Green, H. J., & Patla, A. E. (1988). Human tibialis anterior contractile responses following fatiguing exercise with and without β‐adrenoceptor blockade. Clinical Physiology, 8(3), 215-225.
Amendt, K., Czachurski, J., Dembowsky, K., & Seller, H. (1979). Bulbospinal projections to the intermediolateral cell column; a neuroanatomical study. Journal of the autonomic nervous system, 1(1), 103-117.
Andersson, K. E. (2001). Pharmacology of penile erection. Pharmacological reviews, 53(3), 417-450.
Andersson, K. E., & Arner, A. (2004). Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiological reviews, 84(3), 935-986.
Armando, I., Van Anthony, M. V., & Jose, P. A. (2011). Dopamine and renal function and blood pressure regulation. Comprehensive Physiology, 1(3), 1075.
Asamoto, K. (2005). Network of the sympathetic nervous system: focus on the input and output of the cervical sympathetic ganglion. Anatomical science international, 80, 132-140.
Axelrod FP. Familial dysautonomia. In: Robertson D, Biaggioni I, editors. Disorders of the Autonomic Nervous System. Luxemborg: Harwood Academic Press, 1995, pp. 217-231.
Axelrod, J. (1959). Metabolism of epinephrine and other sympathomimetic amines. Physiological Reviews, 39(4), 751-776.
Bär, K. J. (2015). Cardiac autonomic dysfunction in patients with schizophrenia and their healthy relatives–a small review. Frontiers in Neurology, 6, 139.
Hattori, S., Suda, A., Kishida, I., Miyauchi, M., Shiraishi, Y., Fujibayashi, M., ... & Hirayasu, Y. (2018). Association between dysfunction of autonomic nervous system activity and mortality in schizophrenia. Comprehensive Psychiatry, 86, 119-122.
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005). Schizophrenia and increased risks of cardiovascular disease. American heart journal, 150(6), 1115-1121.
Kendler, K. S., & Engstrom, E. J. (2018). Criticisms of Kraepelin’s psychiatric nosology: 1896–1927. American Journal of Psychiatry, 175(4), 316-326.
Kraepelin, E., & Quen, J. M. (1991). Psychiatry: A textbook for students and physicians. (No Title).
Porges, S. W. (2003). Social engagement and attachment: a phylogenetic perspective. Annals of the New York Academy of Sciences, 1008(1), 31-47.
Porges, S. W. (2007). The polyvagal perspective. Biological psychology, 74(2), 116-143.
Thayer, J. F., & Lane, R. D. (2000). A model of neurovisceral integration in emotion regulation and dysregulation. Journal of affective disorders, 61(3), 201-216.
Thayer, J. F., & Sternberg, E. (2006). Beyond heart rate variability: vagal regulation of allostatic systems. Annals of the New York Academy of Sciences, 1088(1), 361-372.
